MA32610B1 - Polymorphe b de n-(2-aminophenyl)-4-(n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl)-benzamide (ms-275) - Google Patents

Polymorphe b de n-(2-aminophenyl)-4-(n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl)-benzamide (ms-275)

Info

Publication number
MA32610B1
MA32610B1 MA33670A MA33670A MA32610B1 MA 32610 B1 MA32610 B1 MA 32610B1 MA 33670 A MA33670 A MA 33670A MA 33670 A MA33670 A MA 33670A MA 32610 B1 MA32610 B1 MA 32610B1
Authority
MA
Morocco
Prior art keywords
polymorphate
aminophenyl
benzamide
methoxycarbonyl
aminomethyl
Prior art date
Application number
MA33670A
Other languages
Arabic (ar)
English (en)
Inventor
Matthias Schneider
Michael Gottfried
Jens Geisler
Gabriele Winter
Original Assignee
Bayer Shering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41133825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32610(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Shering Pharma Ag filed Critical Bayer Shering Pharma Ag
Publication of MA32610B1 publication Critical patent/MA32610B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne la forme cristalline du polymorphe B de N-(2-aminophényl)-4-[N-(pyridine-3-yl)méthoxy-carbonyaminométhyl]benzamide (MS-275) de formule (I), ainsi que le procédé de production dudit composé, son utilisation comme médicament dans le traitement de maladies spécifiques.
MA33670A 2008-08-29 2011-03-04 Polymorphe b de n-(2-aminophenyl)-4-(n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl)-benzamide (ms-275) MA32610B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
EP08163274 2008-08-29
PCT/EP2009/006381 WO2010022988A1 (fr) 2008-08-29 2009-08-27 Polymorphe b de n-(2-aminophényl)-4-[n-(pyridine-3-yl)-méthoxycarbonyl-aminométhyl]-benzamide (ms-275)

Publications (1)

Publication Number Publication Date
MA32610B1 true MA32610B1 (fr) 2011-09-01

Family

ID=41133825

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33670A MA32610B1 (fr) 2008-08-29 2011-03-04 Polymorphe b de n-(2-aminophenyl)-4-(n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl)-benzamide (ms-275)

Country Status (36)

Country Link
US (2) US7973166B2 (fr)
EP (1) EP2350005B1 (fr)
JP (1) JP4921616B2 (fr)
KR (1) KR101073760B1 (fr)
CN (1) CN102137846B (fr)
AR (1) AR073226A1 (fr)
AT (1) ATE538094T1 (fr)
AU (1) AU2009286982C1 (fr)
BR (1) BRPI0918580B8 (fr)
CA (1) CA2735294C (fr)
CO (1) CO6351736A2 (fr)
CR (2) CR20110107A (fr)
CY (1) CY1112645T1 (fr)
DK (1) DK2350005T3 (fr)
DO (1) DOP2011000064A (fr)
EA (1) EA016811B1 (fr)
EC (1) ECSP11010849A (fr)
ES (1) ES2378640T3 (fr)
HK (1) HK1160107A1 (fr)
HN (1) HN2011000609A (fr)
HR (1) HRP20120183T8 (fr)
IL (1) IL211276A (fr)
MA (1) MA32610B1 (fr)
MX (1) MX2011002248A (fr)
MY (1) MY149058A (fr)
NZ (1) NZ591387A (fr)
PE (2) PE20141062A1 (fr)
PL (1) PL2350005T3 (fr)
PT (1) PT2350005E (fr)
RS (1) RS52164B (fr)
SI (1) SI2350005T1 (fr)
SM (1) SMT201200026B (fr)
SV (1) SV2011003846A (fr)
TW (1) TWI427062B (fr)
WO (1) WO2010022988A1 (fr)
ZA (1) ZA201102285B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2350005T3 (da) 2008-08-29 2012-03-19 Bayer Pharma AG N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3168210A1 (fr) 2015-11-13 2017-05-17 Sandoz Ag Formes crystallines de l'entinostat
WO2017216761A1 (fr) * 2016-06-17 2017-12-21 Dr. Reddy's Laboratories Limited Formes solides d'entinostat
WO2019019130A1 (fr) * 2017-07-28 2019-01-31 杭州领业医药科技有限公司 Composé contenant de l'entinostat, forme cristalline du composé correspondant et procédé de préparation et composition pharmaceutique associés
KR20240019100A (ko) 2021-05-10 2024-02-14 맥파란 스미스 리미티드 엔티노스타트의 신규 형태

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
JP4030683B2 (ja) * 1998-07-24 2008-01-09 三井化学株式会社 ベンズアミド誘導体の合成法
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP4360660B2 (ja) * 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
DK2350005T3 (da) 2008-08-29 2012-03-19 Bayer Pharma AG N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B

Also Published As

Publication number Publication date
PE20141062A1 (es) 2014-09-19
WO2010022988A1 (fr) 2010-03-04
JP2012500819A (ja) 2012-01-12
PT2350005E (pt) 2012-03-12
KR20110038187A (ko) 2011-04-13
US20100056585A1 (en) 2010-03-04
CN102137846A (zh) 2011-07-27
ZA201102285B (en) 2011-12-28
HRP20120183T8 (en) 2012-11-30
AU2009286982C1 (en) 2012-04-26
CN102137846B (zh) 2014-04-23
NZ591387A (en) 2012-03-30
MY149058A (en) 2013-07-15
PE20110677A1 (es) 2011-09-16
JP4921616B2 (ja) 2012-04-25
KR101073760B1 (ko) 2011-10-13
EA016811B1 (ru) 2012-07-30
CY1112645T1 (el) 2016-02-10
SI2350005T1 (sl) 2012-03-30
DK2350005T3 (da) 2012-03-19
AU2009286982A1 (en) 2010-03-04
CA2735294C (fr) 2013-10-15
SV2011003846A (es) 2011-07-27
BRPI0918580A8 (pt) 2017-07-11
CO6351736A2 (es) 2011-12-20
BRPI0918580A2 (pt) 2015-12-01
AR073226A1 (es) 2010-10-20
EP2350005B1 (fr) 2011-12-21
PL2350005T3 (pl) 2012-05-31
IL211276A0 (en) 2011-04-28
HRP20120183T1 (hr) 2012-03-31
AU2009286982B2 (en) 2011-06-23
USRE45499E1 (en) 2015-04-28
US7973166B2 (en) 2011-07-05
DOP2011000064A (es) 2011-03-31
EP2350005A1 (fr) 2011-08-03
CR20160465A (es) 2016-12-06
CA2735294A1 (fr) 2010-03-04
HN2011000609A (es) 2014-09-29
EA201100354A1 (ru) 2011-10-31
ECSP11010849A (es) 2011-03-31
SMT201200026B (it) 2012-07-10
BRPI0918580B1 (pt) 2020-11-24
RS52164B (en) 2012-08-31
TWI427062B (zh) 2014-02-21
ES2378640T3 (es) 2012-04-16
MX2011002248A (es) 2011-03-29
TW201014820A (en) 2010-04-16
IL211276A (en) 2014-07-31
CR20110107A (es) 2011-04-28
HK1160107A1 (en) 2012-08-10
BRPI0918580B8 (pt) 2021-05-25
ATE538094T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
MA32610B1 (fr) Polymorphe b de n-(2-aminophenyl)-4-(n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl)-benzamide (ms-275)
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
EA201200741A1 (ru) Способ получения этексилата дабигатрана
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
CR20120295A (es) Triazolopiridinas
BRPI0911764A2 (pt) inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
BR112012006686A2 (pt) composto amida substituído
SMT201600131B (it) Procedimento per la produzione di piastrine
DK2262793T3 (da) Krystallinske former af nilotinib-hci
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
EA200900945A1 (ru) Новый способ синтеза агомелатина
EA200900946A1 (ru) Новый способ синтеза агомелатина
MA32215B1 (fr) Cristal de compose de benzimidazole
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
BRPI0906441A2 (pt) Composição de concentrado emulsificável
EA200900943A1 (ru) Новый способ синтеза агомелатина
MX2009000198A (es) Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo.
ECSP099554A (es) Nuevo procedimiento de obtención de la forma cristalina v de la agomelatina
GB2462893B (en) N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
EA201591190A1 (ru) Полиморф
DK2128152T3 (da) Fremgangsmåde til rensning af cykliske diestere af L- eller D-mælkesyre
TH109615B (th) อิฐบล๊อก
TH123829B (th) อิฐบล๊อก